Skip to main content
Fig. 11 | Cancer Nanotechnology

Fig. 11

From: Cabazitaxel-loaded human serum albumin nanoparticles combined with TGFβ-1 siRNA lipid nanoparticles for the treatment of paclitaxel-resistant non-small cell lung cancer

Fig. 11

Cypate-CTX-HSA-NPs was distributed in more tissues compared with Cypate-CTX-Tween at different time-points. A Bioluminescence signal distribution in paclitaxel-resistant tumor. B Quantitative analysis of paclitaxel-resistant tumor bioluminescence signals at different time-points. C Ex vivo bioluminescence images of tissues from the tumor, liver, heart, spleen, lung, and kidney at 24 h post-injection. D Quantitative analysis of bioluminescence signals of tissues from the tumor, liver, heart, spleen, lung, and kidney at 24 h post-injection. CCypate = 0.4 mg/kg

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us